US5609631A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Fibrin D-domain multimer coated prostheses and methods for their production
Assignee: McMaster University
•
Filing: 1995-04-28
•
Granted: 1997-03-11
•
Expires: 2015-04-28
Abstract
Abstract Methods for coating a prosthetic surface with anti-thrombogenic, or anti-coagulant, proteins are disclosed. The methods involve contacting a surface of a prosthetic material with a composition containing multimers of fibrin degradation products. These multimers, preferably D-dimers, have cross-linked D-domains. The methods of the invention are useful for providing an anti-thrombogenic coating on prosthetic implants which are exposed to a patient's blood after implantation, for example vascular grafts and artificial heart valves.
Inventors
- 👤 Fraser D. Rubens
- 👤 Paul D. Bishop
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 01:59
CPC Classifications
A; A61; A61L; A61L33/00; A61L33/06; A61L33/12; A61L33/126; A61L27/00; A61L27/28; A61L27/34; Y; Y10; Y10S; Y10S623/00; Y10S623/92; Y10S623/921; Y10S623/922
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
45 words
A method of coating a prosthetic surface with an anti-thrombogenic protein, comprising the step of: contacting said prosthetic surface with a composition comprising multimers of fibrin degradation products, the multimers having cross-linked D-domains, to produce an anti-thrombogenic coating comprising said multimers on said prosthetic surface.
Claim 2
Independent Claim
45 words
A method of coating a prosthetic surface with an anti-thrombogenic protein, comprising the step of: contacting said prosthetic surface with a composition comprising multimers of fibrin degradation products, the multimers having cross-linked D-domains, to produce an anti-thrombogenic coating comprising said multimers on said prosthetic surface.
Claim 3
Dependent Claim
22 words
A method according to claim 1, wherein the composition consists essentially of said multimers of fibrin degradation products in a suitable carrier.
Claim 4
Dependent Claim
29 words
A method according to claim 1, wherein the composition consists of a solution of said multimers substantially free of intact fibrin and fibrin degradation products other than said multimers.
Claim 5
Dependent Claim
29 words
A method according to claim 1, wherein the composition is a solution and a concentration of said multimers in said solution is between approximately 0.1 mg/ml and 10 mg/ml.
Claim 6
Dependent Claim
15 words
A method according to claim 1, wherein the fibrin degradation products are plasmin cleavage products.
Claim 7
Dependent Claim
32 words
A method according to claim 1, wherein the composition is a solution and the prosthetic surface is incubated in the solution at a temperature of between approximately 20° C. and 25° C.
Claim 8
Dependent Claim
34 words
A method according to claim 1, wherein the composition is a solution and the prosthetic surface is incubated in the solution at a temperature of at least 56° C. but less than 100° C.
Claim 9
Dependent Claim
32 words
A method according to claim 1, wherein said multimers are formed by cross-linking intact fibrin with Factor XIII and subsequently generating the degradation products from said cross-linked intact fibrin by plasmin digestion.
Claim 10
Dependent Claim
17 words
A method according to claim 1, wherein the prosthetic surface is formed of a biologically compatible polymer.
Claim 11
Dependent Claim
29 words
A method according to claim 9, wherein the polymer is selected from the group consisting of polyethyleneterephthalate, polytetrafluoroethylene, expanded polytetrafluoroethylene, polymers of lactide-glycolide, polyglactin, polydioxanone, polyurethane, polypropylene and polyester.
Claim 12
Dependent Claim
32 words
A method according to claim 1, wherein the prosthetic surface is formed of a biomedically compatible material selected from the group consisting of stainless steel, titanium, cobalt chrome alloys and silicon-based materials.
Claim 13
Dependent Claim
18 words
A method according to claim 1, wherein the prosthetic surface is a surface of an artificial vascular implant.
Claim 14
Dependent Claim
18 words
A method according to claim 1, further comprising the step of seeding the prosthetic surface with endothelial cells.
Claim 15
Dependent Claim
38 words
A method according to claim 1, wherein the composition contains one or more additional proteins selected from the group consisting of basic fibroblast growth factor, endothelial cell growth factor, α2 macroglobulin, vitronectin, fibronectin, and cell-binding fragments of fibronectin.
Claim 16
Dependent Claim
18 words
A method according to claim 1, wherein the prosthetic surface is a surface of an artificial duct implant.
Claim 17
Dependent Claim
38 words
A method according to claim 15, wherein the artificial duct implant is selected from the group consisting of artificial urinary ducts, artificial kidney tubules, artificial lymphatic ducts, artificial bile ducts, artificial pancreatic ducts, indwelling catheters, shunts and drains.
Claim 18
Dependent Claim
47 words
A method according to claim 1, wherein the prosthetic surface is selected from the group consisting of a stent surface, an artificial urological implant surface, an artificial heart valve surface, an artificial internal organ surface, an artificial bone implant surface, a patch surface and a web surface.
Claim 19
Dependent Claim
22 words
A method according to claim 1, wherein the prosthetic surface is a surface of a heterograft or xenograft tissue or organ implant.
Claim 20
Dependent Claim
16 words
A prosthetic member comprising: a coated prosthetic surface prepared according to the process of claim 1.
Claim 21
Independent Claim
76 words
A method of coating a prosthetic surface with an anti-thrombogenic protein, comprising the steps of: contacting said prosthetic surface with a composition comprising multimeric fibrin degradation products in a suitable carrier, said multimeric fibrin degradation products having cross-linked D-domains and said composition being substantially free of intact fibrin and fibrin degradation products other than said multimeric fibrin degradation products, to produce an anti-thrombogenic coating consisting essentially of said multimeric fibrin degradation products on said prosthetic surface.
Claim 22
Independent Claim
76 words
A method of coating a prosthetic surface with an anti-thrombogenic protein, comprising the steps of: contacting said prosthetic surface with a composition comprising multimeric fibrin degradation products in a suitable carrier, said multimeric fibrin degradation products having cross-linked D-domains and said composition being substantially free of intact fibrin and fibrin degradation products other than said multimeric fibrin degradation products, to produce an anti-thrombogenic coating consisting essentially of said multimeric fibrin degradation products on said prosthetic surface.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-03-10 | 2000-09-09 | 2001-03-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-03-10 | 2004-09-09 | 2005-03-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-03-10 | 2008-09-09 | 2009-03-11 | $7700.00 | Window Closed / Lapsed |